Cobenfy is a new medication for the treatment of schizophrenia. It consists of a muscarinic agonist called xanomeline and a muscarinic antagonist called trospium. However, the associated gastrointestinal side effects, especially constipation, have a potential effect on compliance. Currently, there is no widely standardized constipation prevention protocol during Cobenfy therapy. We present a case of constipation during the treatment of schizoaffective disorder with Cobenfy in a middle-aged female. We conducted a literature review on Cobenfy therapeutic management strategies and provide constipation prevention strategies.
Ezema et al. (2026) studied this question.